Ruxolitinib has been shown to prolong survival and improve symptoms by inhibiting the JAK-STAT signaling pathway.[1,6] However, ruxolitinib also exerts immunosuppressive effects by regulating both the innate and adaptive immune systems, leading to the suppression of proinflammatory cytokines.[7,8] Consequently, this immunosuppression increases the risk of opportunistic infections, as evidenced by a recent multi-center patient-reported pilot study that included 948 unselected myeloproliferative neoplasms patients. Here, SOAT1 is linked to myeloproliferative disorder.